hCDR1 (Edratide)
Systemic Lupus Erythematosus (SLE)
Key Facts
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. is a publicly traded, clinical-stage company with a mission to address unmet needs in autoimmune diseases through the strategic acquisition and development of late-stage drug candidates. Its primary achievement is the advancement of its lead peptide asset, hCDR1, through multiple clinical trials for systemic lupus erythematosus and lupus nephritis. The company's strategy centers on a lean, capital-efficient model focused on de-risking and enhancing the value of specific assets for potential partnerships or strategic exits. XTL operates from its headquarters in Rehovot, Israel, leveraging its expertise in asset selection and clinical development within its focused therapeutic niche.
View full company profileAbout XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. is a publicly traded, clinical-stage company with a mission to address unmet needs in autoimmune diseases through the strategic acquisition and development of late-stage drug candidates. Its primary achievement is the advancement of its lead peptide asset, hCDR1, through multiple clinical trials for systemic lupus erythematosus and lupus nephritis. The company's strategy centers on a lean, capital-efficient model focused on de-risking and enhancing the value of specific assets for potential partnerships or strategic exits. XTL operates from its headquarters in Rehovot, Israel, leveraging its expertise in asset selection and clinical development within its focused therapeutic niche.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| Nipocalimab | johnson-and-johnson-innovative-medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Telitacicept (RC18) | RemeGen | Approved |
| Cenerimod | Ono Pharmaceutical | Phase 3 |